The Filing Desk

Compugen vs Recursion Pharmaceuticals

Compugen CGEN · Recursion Pharmaceuticals RXRX · Biotechnology

Recursion Pharmaceuticals reported revenue of $75 million in fiscal 2025, about the same as Compugen's $73 million in fiscal 2025. Compugen's revenue grew 161.1% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. Compugen had an operating margin of 43.0%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was $31 million at Compugen and −$378 million at Recursion Pharmaceuticals.

Side by side

CompugenRecursion Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$73M$75M
Revenue growth161.1%26.9%
Revenue growth a year, last 5 years105.2%79.6%
Gross margin87.3%5.0%
Operating margin43.0%−867.9%
Net margin48.6%−863.4%
Free cash flow$31M−$378M
Free cash flow margin43.0%−506.5%
Return on capital—−117.2%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.8%63.2%
Last close$1.88$2.72
P/E at the last close——
Insider trades, last 12 monthssold $118,302sold $6.9 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CompugenRecursion Pharmaceuticals
Operating margin
Percent of revenue
CompugenRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CompugenRecursion Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Compugen and Recursion Pharmaceuticals pages.